The therapeutic landscape of multiple sclerosis has changed profoundly, with an expanding range of disease-modifying therapies targeting distinct biological pathways. Yet treatment remains largely organized around sequential use of individual therapies, while MS continues to evolve through interacting inflammatory, neurodegenerative and reparative processes.
This creates an important scientific opportunity: can complementary therapeutic mechanisms be rationally integrated, either through combination strategies or through more precisely optimized treatment sequences, to address the complexity and changing biology of MS?
Realizing this potential will require more than additional therapeutic options. It requires a stronger biological rationale for combining or sequencing treatments, robust approaches to defining benefit and risk, innovative trial designs, and integration of clinical-trial and real-world evidence.
This workshop will bring together leading experts across MS and related fields to examine the evidence to date, explore emerging therapeutic concepts—including immunotherapy, neuroprotection and repair—and address the methodological, safety, regulatory and practical challenges involved.
The ultimate goal is to define a forward-looking research framework for determining when, how and in whom combination or sequential strategies should be investigated, and how they might reshape the future treatment paradigm in MS.